Predict your next investment

Allay Therapeutics company logo
HEALTHCARE | Drug Discovery
allaytx.com

See what CB Insights has to offer

Founded Year

2016

Stage

Series C | Alive

Total Raised

$90.75M

Last Raised

$60M | 1 mo ago

About Allay Therapeutics

Allay Therapeutics is pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation for patients and physicians. The company's proprietary technology platform combines validated non-opioid analgesics and biopolymers to create dissolvable candidates to deliver pain relief within a targeted site over weeks: an order of magnitude greater than the longest-lasting pain treatments currently available.

Allay Therapeutics Headquarter Location

4040 Campbell Avenue Suite 110

Menlo Park, California, 94025,

United States

Latest Allay Therapeutics News

Temasek invests in US biotech firm Allay Therapeutics

Sep 16, 2021

The Straits Times Allay Therapeutics aims to craft therapies for long-lasting pain management.PHOTO: ALLAY THERAPEUTICS Olivia Poh They can read the article in full after signing up for a free account. Share link: All done! This article is now fully available for you Read now Get unlimited access to all stories at $0.99/month for the first 3 months. Get unlimited access to all stories at $0.99/month for the first 3 months. Let's go! Spin the wheel now SINGAPORE (THE BUSINESS TIMES) - Allay Therapeutics, a clinical-stage biotech start-up that makes pain relief products, raised US$60 million (S$80.45 million) in a Series C fund-raising round led by United States-based healthcare-focused venture capital firm Arboretum Ventures. Temasek, Temasek's subsidiary Pavilion Capital, as well as Temasek-linked Vertex Growth and Vertex Ventures HC participated in the round; there was no shortage of other crossover investors, including from Australia and Taiwan. Other investors included US-based NEA, Australian life science investor Brandon Capital Partners and WTT Investment, the Taiwan-based single family office of Fubon Group founder Tsai Wan-Tsai. Founded in 2017, Allay Therapeutics aims to craft therapies for long-lasting pain management, hoping to reduce the need for opioid use after surgery. Its lead product, ATX-101, is a coin-sized implant that delivers painkillers to a targeted site over weeks. The US-based biotech plans to spend the money to advance the company's lead product into Phase 2B clinical trials, when its implant ATX-101 is to be studied for use in knee replacement surgeries in the US. Funds will also be used for future developments of its platform. Allay Therapeutics, which has research and development teams in Singapore and San Francisco, intends to "advance at least one new clinical candidate into clinical trials each year". It is currently building out its manufacturing capabilities in the San Francisco Bay Area to support future product launches. Researchers have developed proof-of-concept of variations of new implants and injectable formulations, among others, it said. Arboretum Ventures managing partner Nicole Walker said that the demand for total knee replacement surgery is "growing dramatically", and with it, so will the "desire for non-opioid solutions" for pain relief. "We believe that Allay's technology platform offers unprecedented potential breadth in terms of applicability and therapeutic profile for pain management, an area in need of innovation," she said. More on this topic

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Allay Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Allay Therapeutics is included in 1 Expert Collection, including Biopharmaceuticals.

B

Biopharmaceuticals

14,138 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Allay Therapeutics Patents

Allay Therapeutics has filed 1 patent.

The 3 most popular patent topics include:

  • Amines
  • Dosage forms
  • Drug delivery devices
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/11/2019

Drug delivery devices, Transcription factors, Dosage forms, Amines, Pharmacokinetics

Application

Application Date

4/11/2019

Grant Date

Title

Related Topics

Drug delivery devices, Transcription factors, Dosage forms, Amines, Pharmacokinetics

Status

Application

Allay Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Allay Therapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.